Key Highlights
- Janux Therapeutics appoints Eric Dobmeier and Natasha Hernday to Board of Directors.
- David Campbell, Ph.D., highlights their experience and leadership as crucial for Janux’s growth.
- Eric Dobmeier previously led Chinook Therapeutics through strategic growth, resulting in a $3.5 billion acquisition by Novartis.
- Natasha Hernday played key roles in high-value transactions at Seagen Inc. and Amgen, culminating in Seagen’s $43 billion acquisition by Pfizer.
- Jay Lichter, Ph.D., resigns from the Board, with Ronald W. Barrett, Ph.D., taking over as Chairperson.
Source: Business Wire
Notable Quote
- “Eric and Natasha’s vast experience and proven leadership in the biopharmaceutical industry are tremendous assets for Janux at this pivotal stage of our growth. Their contributions will not only enhance our strategic direction but ultimately benefit patients through the potential development of next-generation cancer therapies.” — David Campbell, Ph.D., President and CEO at Janux Therapeutics
SoHC's Take
The strategic appointment of Eric Dobmeier and Natasha Hernday to Janux Therapeutics’ Board of Directors signifies a robust step forward in the company’s mission to advance its pipeline of novel immunotherapies. Dobmeier’s extensive operational experience and Hernday’s successful track record in strategic transactions are poised to enhance Janux’s growth trajectory. Their leadership is expected to drive innovative approaches in cancer therapy, bolstering Janux’s position in the biopharmaceutical landscape. Furthermore, the transition in board leadership from Jay Lichter to Ronald W. Barrett ensures continuity and stability as Janux navigates its next phase of development and clinical trials.
